Adicet Bio, Inc. - Common Stock (ACET)
1.0300
+0.0200 (1.98%)
Adicet Bio Inc. is a biotechnology company focused on developing innovative cell therapies for cancer and other diseases
The company specializes in utilizing its proprietary technology to engineer immune cells, particularly gamma delta T cells, to effectively target and eradicate tumor cells. By harnessing the body's immune system, Adicet aims to create next-generation therapeutic solutions that can provide patients with more effective and personalized treatments, thereby advancing the field of immunotherapy and improving outcomes in oncology.
![](https://cdn.benzinga.com/files/images/story/2024/09/11/analyst-ratings-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 11, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 13, 2024
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1.jpg)
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news
Via InvestorPlace · June 10, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 14, 2024
![](https://investorplace.com/wp-content/uploads/2021/08/penny-stocks-1600.jpg)
Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements.
Via InvestorPlace · March 28, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ACET stock results show that Adicet Bio met analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 19, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga · November 9, 2023
![](https://investorplace.com/wp-content/uploads/2024/01/growthstocks1600-2.png)
With the S&P 500 at record highs, betting on these high-risk stocks that could pay off is a tantalizing prospect at this time.
Via InvestorPlace · March 5, 2024
![](https://investorplace.com/wp-content/uploads/2021/12/penny-stocks-1600.jpg)
Unlock value in penny stocks amid bullish S&P 500 trends and shifting monetary policies, focusing on businesses with solid drivers
Via InvestorPlace · February 27, 2024
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.
Via InvestorPlace · February 25, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 22, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/22/screenshot_2024-01-22_at_6.43.16_pm.png?width=1200&height=800&fit=crop)
IN8bio (NASDAQINAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.
Via Benzinga · January 22, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/09/jetblue_airways_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of JetBlue Airways Corporation (NASDAQJBLU) fell sharply during Tuesday’s session.
Via Benzinga · January 9, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 9, 2024
![](https://cdn.benzinga.com/files/images/story/2024/BZ-Stock-Whisper-Index-Logo-6.jpeg?width=1200&height=800&fit=crop)
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via Benzinga · January 5, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/04/image39.jpeg?width=1200&height=800&fit=crop)
Shares of Mobileye Global Inc. (NASDAQMBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
Via Benzinga · January 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 8, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/27/screenshot_2023-11-27_at_7.23.33_pm.png?width=1200&height=800&fit=crop)
Why Are Gamma-Delta T Cells Important In Fighting Cancer?
Via Benzinga · November 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/27/acet_0.png?width=1200&height=800&fit=crop)
JMP Securities downgraded Adicet Bio Inc (NASDAQACET) to a Market Perform (from Market Outperform) and removed the
Via Benzinga · June 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/27/td_synnex_-_logo.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow traded up 0.73% to 33,959.64 while the NASDAQ rose 1.75% to 13,569.42. The S&P 500, also rose, gaining, 1.22% to 4,381.53.
Via Benzinga · June 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/27/walgreens_-_logo_0.jpg?width=1200&height=800&fit=crop)
Gainers Tivic Health Systems, Inc. (NASDAQTIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
Via Benzinga · June 27, 2023